Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group

The Journal of Clinical Endocrinology and Metabolism
C RouxB Cortet

Abstract

Osteoporosis is a well-recognized adverse effect of corticosteroid therapy. This study aimed to investigate the effect of etidronate, intermittent cyclical therapy, in the prevention of corticosteroid-induced bone loss. Patients with various medical conditions starting high-dose corticosteroid therapy were enrolled in the study. The treatment had to be expected to continue for at least 12 months with the initial 90 days at a mean daily dose of at least 7.5 mg of prednisone, with subsequent treatment of at least 2.5 mg/day. One hundred seventeen patients were randomly assigned oral etidronate 400 mg/day, or placebo, for 14 days, followed by 76 days of oral calcium carbonate (500 mg elemental calcium), cycled over 12 months. The primary outcome measure was the difference in percent change from baseline in bone mineral density of the lumbar spine between the groups at the end of year 1. Secondary measures included changes in femur bone density and in biochemical markers of bone remodeling. The mean (+/- SEM) lumbar spine bone density changed 0.30 +/- 0.61% and -2.79 +/- 0.63% in the etidronate and placebo groups, respectively. The mean difference between groups after 1 yr was 3.0 +/- 0.84% (P = 0.004). The changes in the femoral n...Continue Reading

Citations

Feb 14, 2006·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Albrecht W PoppKurt Lippuner
Jun 26, 2001·British Journal of Clinical Pharmacology·T P van StaaH G Leufkens
Apr 1, 2009·Therapeutic Advances in Musculoskeletal Disease·Lisa-Ann Fraser, Jonathan D Adachi
Jan 15, 2014·Trends in Endocrinology and Metabolism : TEM·Holger HenneickeMarkus J Seibel
Sep 14, 2006·Calcified Tissue International·T P van Staa
Dec 3, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Karine BriotUNKNOWN Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO)
Jul 17, 2009·Current Rheumatology Reports·Pantelis Panopalis, Jinoos Yazdany
May 4, 2006·Clinical Rheumatology·Margaret GourlayYevgeniy Sheyn
Nov 24, 2006·Clinical Rheumatology·Johann D Ringe, Parvis Farahmand
Aug 7, 2002·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Shreyasee AminDavid T Felson
Aug 11, 2012·Calcified Tissue International·R RizzoliJ Y Reginster
Sep 6, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Adrianne C FeldsteinMichael Herson
Oct 12, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Jean-Pierre DevogelaerYves Boutsen
Oct 7, 2011·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C RouxP N Sambrook
Mar 22, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·S LekamwasamUNKNOWN Joint IOF-ECTS GIO Guidelines Working Group
Feb 25, 2009·Expert Opinion on Drug Safety·Liron Caplan, Kenneth G Saag
Dec 6, 2005·Joint, Bone, Spine : Revue Du Rhumatisme·Philippe Orcel
Feb 5, 2015·Endocrine·Maurizio RossiniDavide Gatti
Jan 6, 2001·The Annals of Pharmacotherapy·M E ElliottA Gudmundsson
Dec 24, 2015·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M A AmicheS M Cadarette
Jan 10, 2001·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Y BoutsenJ P Devogelaer
Jul 24, 2001·PharmacoEconomics·P VestergaardL Mosekilde
Feb 8, 2006·Clinical Orthopaedics and Related Research·Pietra PennisiRené Rizzoli
Jan 20, 2016·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M A AmicheS M Cadarette
Nov 3, 1998·Journal of Internal Medicine·R EastellD J Torgerson
Dec 21, 2000·Current Rheumatology Reports·P BoulosJ D Adachi
Apr 19, 2005·Treatments in Endocrinology·Ann Cranney, Jonathan D Adachi
Jul 4, 2001·Drugs·M SharpeC M Spencer
Aug 2, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·J D Adachi, A Papaioannou
Nov 2, 2016·The Cochrane Database of Systematic Reviews·Claire S AllenJoanne Homik
Jan 13, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Stephen F HodgsonUNKNOWN AACE Osteoporosis Task Force
Jan 29, 2008·Revista clínica española·M Sosa HenríquezUNKNOWN Sociedad Española de Medicina Interna

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.